Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flavopiridol, Cytarabine, and Mitoxantrone in Poor-Risk Acute Leukemias
NCT00016016Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2001
- Primary completion
- Nov 2006
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alvocidib in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Primary endpoints: Dose-Limiting Toxicity at 35 days and Complete Remission at 6 years. Started Feb 2001; status: completed.
02
Drugs
alvocidib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00016016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016016.